myBiometry leverages advanced biomarker technology to empower asthma patients by providing critical biological data that can predict and prevent asthma attacks. Central to their approach is a patented sensor and device that measures airway inflammation through the analysis of fractional exhaled nitric oxide (FeNO). This measurement allows for a biological assessment of a patient's risk of experiencing an asthma attack, as well as insights into medication adherence, efficacy, and exposure to environmental triggers. By integrating this biomarker data with clinical and environmental risk factors, myBiometry aims to identify the root causes of symptoms and poor asthma control.

The company employs a sophisticated prediction engine that aggregates guideline-based risk factors to create personalized, predictive risk models for each patient. This technology not only provides actionable insights but also enables proactive patient engagement before symptoms arise. Through their app, myBiometry delivers guideline-based coaching and education, facilitating self-management of asthma for millions of patients. Their self-management programs, recognized by the CDC, are designed to improve asthma control and reduce healthcare costs, showcasing the potential of data science in transforming healthcare delivery for chronic conditions like asthma.

United States

myBiometry is a platform to remotely monitor and manage patients with chronic conditions using software and biomarker data generated from proprietary sensors. Our initial focus is asthma.

myBiometry

Company Details